SEC Info  
    Home      Search      My Interests      Help      Sign In      Please Sign In

ResMed Inc. – ‘8-K’ for 11/16/22

On:  Thursday, 11/17/22, at 4:08pm ET   ·   For:  11/16/22   ·   Accession #:  1193125-22-287662   ·   File #:  1-15317

Previous ‘8-K’:  ‘8-K’ on / for 10/27/22   ·   Next:  ‘8-K’ on 1/26/23 for 1/25/23   ·   Latest:  ‘8-K’ on / for 1/24/24

Find Words in Filings emoji
 
  in    Show  and   Hints

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

11/17/22  ResMed Inc.                       8-K:5      11/16/22   10:159K                                   Donnelley … Solutions/FA

Current Report   —   Form 8-K

Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 8-K         Current Report                                      HTML     44K 
 5: R1          Document and Entity Information                     HTML     47K 
 8: XML         IDEA XML File -- Filing Summary                      XML     12K 
 6: XML         XBRL Instance -- d606608d8k_htm                      XML     13K 
 7: EXCEL       IDEA Workbook of Financial Reports                  XLSX      8K 
 3: EX-101.LAB  XBRL Labels -- rmd-20221116_lab                      XML     55K 
 4: EX-101.PRE  XBRL Presentations -- rmd-20221116_pre               XML     35K 
 2: EX-101.SCH  XBRL Schema -- rmd-20221116                          XSD     12K 
 9: JSON        XBRL Instance as JSON Data -- MetaLinks               12±    18K 
10: ZIP         XBRL Zipped Folder -- 0001193125-22-287662-xbrl      Zip     12K 


‘8-K’   —   Current Report


This is an HTML Document rendered as filed.  [ Alternative Formats ]



 iX: 
  8-K  
 i RESMED INC  i US  i false  i 0000943819 0000943819 2022-11-16 2022-11-16

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

FORM  i 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

 i November 16, 2022

Date of Report (Date of earliest event reported)

 

 

ResMed Inc.

(Exact Name of Registrant as Specified in Charter)

 

 

 

 i Delaware    i 001-15317    i 98-0152841

(State or Other Jurisdiction

of Incorporation)

  (Commission
File Number)
 

(I.R.S. Employer

Identification No.)

 

 i 9001 Spectrum Center Boulevard
 i San Diego,  i California  i 92123
(Address of Principal Executive Offices) (Zip Code)

 i (858)  i 836-5000

(Registrant’s telephone number, including area code)

N/A

(Former Name or Former Address, if Changed Since Last Report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

 i 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

 i 

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

 i 

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

 i 

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

 

Trading
Symbol(s)

 

Name of each exchange
on which registered

 i Common Stock, $0.004 par value    i RMD    i NYSE

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter) ☐

Emerging growth company  i 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act ☐

 

 

 


Item 5.07.

Submission of Matters to a Vote of Security Holders.

On November 16, 2022, at our annual meeting of stockholders, our stockholders (1) elected the ten nominees listed below to serve on our board of directors; (2) ratified the selection of KPMG LLP as our independent registered public accounting firm for the fiscal year ending June 30, 2023; and (3) approved, on an advisory basis, the compensation of our named executive officers (“say-on-pay”).

 

     For      Against      Abstain      Broker
Non-Votes
 
Item of business 1: Elect the following seven directors, each to serve until our 2023 annual meeting and until their successors are elected and qualified:            

Carol Burt

     112,920,252        1,611,838        653,168        4,934,277  

Jan De Witte

     114,414,039        549,367        221,852        4,934,277  

Karen Drexler

     112,325,192        2,592,899        267,167        4,934,277  

Michael Farrell

     114,166,629        811,588        207,041        4,934,277  

Peter Farrell

     110,955,680        3,892,880        336,698        4,934,277  

Harjit Gill

     113,995,558        965,687        224,013        4,934,277  

John Hernandez

     113,649,577        1,311,352        224,329        4,934,277  

Richard Sulpizio

     102,238,286        12,686,008        260,964        4,934,277  

Desney Tan

     114,124,829        836,885        223,544        4,934,277  

Ronald Taylor

     102,459,467        12,464,667        261,124        4,934,277  
     For      Against      Abstain      Broker
Non-Votes
 
Item of business 2: Ratify our selection of KPMG LLP as our independent registered public accounting firm for the fiscal year ending June 30, 2023.      113,914,469        6,001,739        203,327     
     For      Against      Abstain      Broker
Non-Votes
 
Item of business 3: Approve, on an advisory basis, the compensation of our named executive officers, as disclosed in our proxy statement (“say-on-pay”).      103,364,254        11,566,190        254,814        4,934,277  


SIGNATURES

We have authorized the person whose signature appears below to sign this report on our behalf, in accordance with the Securities Exchange Act of 1934.

 

    RESMED INC.
Date: November 17, 2022     By:  

/s/ David Pendarvis

      David Pendarvis
      Chief administrative officer, global general counsel and
secretary

Dates Referenced Herein   and   Documents Incorporated by Reference

This ‘8-K’ Filing    Date    Other Filings
6/30/23
Filed on:11/17/22
For Period end:11/16/224
 List all Filings 
Top
Filing Submission 0001193125-22-287662   –   Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)

Copyright © 2024 Fran Finnegan & Company LLC – All Rights Reserved.
AboutPrivacyRedactionsHelp — Thu., Mar. 28, 4:30:12.2pm ET